Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

MPS Iiia: early-phase trial registry

1 of 1 indexed MPS Iiia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

MPS Iiia: 1 US clinical trial tracked, 1 recruiting.

MPS Iiia is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Ultragenyx Pharmaceutical, running 1 of these trials.

Enrollment posture brief

Registry condition mps-iiia

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

MPS Iiia (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near MPS Iiia

MPS Iiia lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for MPS Iiia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. MPS Iiia is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on MPS Iiia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Adjuvant IM Therapy Drug
1 trials
Optimized Prophylactic IM Therapy Drug
1 trials
Prophylactic Immunomodulatory (IM) Therapy Drug
1 trials
UX111 Biological
1 trials

US sites by state

Facility locations filed on MPS Iiia trials. A trial with sites in several states counts in each.

Pennsylvania 1 trials
Ohio 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this MPS Iiia page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This MPS Iiia condition card totals 1 registered trials; most-linked intervention Adjuvant IM Therapy; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.